<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732316</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000600347</org_study_id>
    <secondary_id>AMC-UUCM-2008-0037</secondary_id>
    <nct_id>NCT00732316</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome</brief_title>
  <official_title>HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and antithymocyte globulin before a donor stem
      cell transplant helps stop the growth of cancer and abnormal cells. It may also stop the
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune cells and help destroy any remaining cancer and abnormal cells
      (graft-versus-tumor effect).

      PURPOSE: This phase II trial is studying how well a donor stem cell transplant works after
      busulfan, fludarabine, and antithymocyte globulin in treating patients with hematologic
      cancer or myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To evaluate the efficacy of HLA-haploidentical familial donor hematopoietic cell
           transplantation with a reduced-intensity conditioning regimen of busulfan, fludarabine
           phosphate, and anti-thymocyte globulin in patients with hematologic malignancies or
           myelodysplastic syndromes.

      OUTLINE: Before receiving the reduced-intensity conditioning regimen, patients receive one
      dose of intrathecal (IT) methotrexate, then leucovorin calcium IV or orally 4 hours after
      methotrexate and every 6 hours for a total of 8 doses.

        -  Reduced-intensity conditioning regimen: Patients receive busulfan IV over 6 hours on
           days -7 and -6, fludarabine phosphate IV over 30 minutes on days -7 to -2,
           anti-thymocyte globulin (ATG) IV over 4 hours on days -4 to -1, and methylprednisolone
           IV over 30 minutes on days -4 to -1.

        -  HLA-haploidentical familial donor hematopoietic stem cell transplantation (HSCT):
           Patients undergo allogeneic HSCT over 1 hour on days 0 and 1.

        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV* over 2-4
           hours every 12 hours on days -1 to 30 followed by a taper until day 60 and methotrexate
           IV on days 2, 4 , 7, and 12.

      NOTE: *Cyclosporine can be given orally once oral medication can be tolerated

        -  CNS prophylaxis: When blood counts recover, patients with acute leukemia or chronic
           myelogenous leukemia in blastic crisis resume IT methotrexate once every 2 weeks for a
           total of 4 doses (including the dose given before the conditioning regimen) and
           leucovorin calcium IV or orally 4 hours after (each dose of methotrexate) and every 6
           hours for a total of 8 doses.

      After completion of study treatment, patients are followed periodically for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response</measure>
    <time_frame>about 4-8 weeks after transplantation</time_frame>
    <description>leukemia CR, CR duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor cell engraftment (neutrophil, platelet, and red blood cells)</measure>
    <time_frame>10-35 days after transplantation</time_frame>
    <description>neutrophi count over 500/ul</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic graft-versus-host disease</measure>
    <time_frame>15-100 days; 100 days to 4 years</time_frame>
    <description>ocurrence of acute or chronic GVHD</description>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following hematological malignancies:

               -  Acute leukemia, including any of the following:

                    -  Refractory acute leukemia

                    -  Acute leukemia beyond first remission

                    -  Acute leukemia in first remission with intermediate to poor prognostic
                       features as suggested by chromosomal findings

               -  Chronic myelogenous leukemia (CML)

                    -  Second chronic phase

                    -  Accelerated phase

                    -  Blastic phase

               -  Myelodysplastic syndrome (MDS)

                    -  High-risk MDS (refractory anemia with excess blasts [RAEB], RAEB in
                       transformation, and chronic myelomonocytic leukemia) can be transplanted
                       without prior therapy or after prior therapy failure with hypomethylating
                       agents

                    -  Low-risk MDS can be considered for transplantation after prior therapy
                       failure with immunosuppressive or hypomethylating agents

          -  No willing, suitable HLA-matched donor in family or in donor registries

               -  Patients with active hematologic malignancy, who are felt to be in urgent need of
                  allogeneic hematopoietic cell transplantation, can enroll without a search for
                  HLA-matched unrelated donors

          -  Related donor with HLA-haploidentical mismatch at 3 or less of 6 loci available

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Bilirubin &lt; 2.0 mg/dL

          -  Creatinine &lt; 2.0 mg/dL

          -  AST &lt; 3 times upper limit of normal

          -  Ejection fraction &gt; 40% by MUGA

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo H. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.</citation>
    <PMID>21715313</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyoo-Hyung Lee</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

